ArticleJournal of virus eradication2025
Population immunity to the three serotypes of poliovirus post-interruption of wild poliovirus transmission in Nigeria.
Article in Journal of virus eradication, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The presence of neutralizing antibodies is considered a surrogate marker of protection against the three serotypes of poliovirus. The need to use the Microneutralization test in assessing the neutralizing antibodies to the three serotypes of polioviruses among vaccinated children aged 1-15 years informed this study. Of 400 children tested, 309 (77.3 %), 253 (63.3 %), and 308 (77.0 %) had neutralizing antibodies against P1, P2, and P3, respectively. Only 191 (47.8 %) had neutralizing antibodies against P1P2P3 simultaneously, the global target. Whilst 91 (22.8 %) had no neutralizing antibodies against P1, these children were protected against P2 (23.0 %) and P3 (43.9 %). Similarly, 147 (36.8 %) children had no neutralizing antibodies against P2, but were protected against P1 (66.0 %) and P3 (65.3 %). Furthermore, 52(13 %), 51(12.8 %), and 52 (13.0 %) had no neutralizing antibodies against the combination of P1P3, P1P2, and P2P3, respectively. Only 34 (8.5 %) of the children had no nAb to any of the three serotypes. The optimal number of Polio vaccine doses for effective immunity varied depending on the serotype. Also, gender differences may favor the speed at which children achieve the target antibody titers. Higher antibody titers (1:1280) were observed for P2 and P3, with six of the children having a titer of 1:10240 for P3. The combination of supplementary immunization activities and routine immunization generated a robust immune response across all poliovirus serotypes, in contrast to each of the two. The administrative data and population immunity were not commensurate. New strategies to increase immunity against the P1P2P3 simultaneously in all age groups are urgently required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.